Skip to main content

Revvity

Revvity, Inc., formerly PerkinElmer, is an American life sciences and diagnostics company that provides reagents, cell analysis instruments, imaging systems, and specialized laboratory services globally. The company operates through two primary reporting business segments: Life Sciences and Diagnostics. Its principal revenue drivers stem from commercial sales of diagnostic assay kits, newborn screening systems, genomic reagents, image analysis hardware, and contract research services provided to pharmaceutical companies and clinical reference labs. Revvity holds a market-leading global position in newborn screening technologies, gene editing reagents, and drug discovery assay platforms, having rebranded from PerkinElmer following the divestiture of its legacy applied markets business. The enterprise serves global biopharmaceutical developers, healthcare providers, academic research institutions, and clinical laboratories. The company focuses on expanding gene therapy research tools, broadening oncology diagnostic assays, automating high-throughput screening platforms, and growing its global life sciences presence. Revvity, Inc. is headquartered in Waltham, Massachusetts, United States, and its common stock is publicly listed and traded on the New York Stock Exchange.

14 of the funds FundTelligence covers report a position in Revvity.

Legal name
Revvity Inc
Sector
Health Care
Country
United States
Funds holding it
14

Funds holding Revvity

Showing the 8 largest of 14 funds holding it.

Loading...